Pathstone Holdings
TGTX icon

Pathstone Holdings’s TG Therapeutics TGTX Stock Holding History

Pathstone Holdings’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$463K Buy
+8,430
New +$345K ﹤0.01% 1905
2025
Q4 		– Sell
-7,930
Closed -$286K – 2385
2025
Q3 		$286K Buy
+7,930
New +$261K ﹤0.01% 2049
2025
Q2 		– Sell
-5,365
Closed -$212K – 2340
2025
Q1 		$212K Buy
+5,365
New +$181K ﹤0.01% 2060

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Pathstone Holdings's TGTX Position: Q2 2026 in Review

Pathstone Holdings opened a new position in TG Therapeutics (TGTX) in Q2 2026: 8,430 shares worth $463K. The stake represents ﹤0.01% of the portfolio and ranks #1905 among its holdings. This is a return to the name: Pathstone Holdings previously reported a position in TGTX as recently as Q3 2025.

Pathstone Holdings first reported a position in TGTX in Q1 2025 and has held it in 3 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Pathstone Holdings held 8,430 shares of TG Therapeutics worth $463K as of Q2 2026.
  • TG Therapeutics was a new Pathstone Holdings position in Q2 2026.
  • TG Therapeutics made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #1905 holding.
  • Pathstone Holdings first reported a position in TG Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.